Skip to main content
Erschienen in: Current Gastroenterology Reports 3/2018

01.03.2018 | Large Intestine (B Cash, Section Editor)

Contemporary Management of Ulcerative Colitis

verfasst von: Rohini Vanga, Millie D. Long

Erschienen in: Current Gastroenterology Reports | Ausgabe 3/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

We discuss the newest evidence-based data on management of ulcerative colitis (UC). We emphasize risk-stratification, optimizing medical therapies, and surgical outcomes of UC.

Recent Findings

Recent medical advances include introduction of novel agents for UC. Vedolizumab, an anti-adhesion molecule, has demonstrated efficacy in moderate to severe UC. Tofacitinib, a small molecule, has also demonstrated efficacy. Data on optimization of infliximab show the superiority of combination therapy with azathioprine over monotherapy with infliximab or azathioprine alone. Data on anti-tumor necrosis factor-alpha (anti-TNF) therapeutic drug monitoring also hold promise, as do preliminary data on the dose escalation of infliximab in severe hospitalized UC. Surgical outcome data are reassuring, with new fertility data showing the effectiveness of in vitro fertilization.

Summary

UC management is multi-disciplinary and changing. While novel therapies hold promise, better optimization of our current arsenal will also improve outcomes.
Literatur
1.
Zurück zum Zitat Kappelman MD, Moore KR, Allen JK, Cook SF. Recent trends in the prevalence of Crohn’s disease and ulcerative colitis in a commercially insured US population. Dig Dis Sci. 2013;58(2):519–25.CrossRefPubMed Kappelman MD, Moore KR, Allen JK, Cook SF. Recent trends in the prevalence of Crohn’s disease and ulcerative colitis in a commercially insured US population. Dig Dis Sci. 2013;58(2):519–25.CrossRefPubMed
2.
Zurück zum Zitat Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46–54.e42. quiz e30 CrossRefPubMed Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46–54.e42. quiz e30 CrossRefPubMed
3.
Zurück zum Zitat Targownik LE, Singh H, Nugent Z, Bernstein CN. The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am J Gastroenterol. 2012;107(8):1228–35.CrossRefPubMed Targownik LE, Singh H, Nugent Z, Bernstein CN. The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am J Gastroenterol. 2012;107(8):1228–35.CrossRefPubMed
4.
Zurück zum Zitat Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007;5(1):103–10.CrossRefPubMed Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007;5(1):103–10.CrossRefPubMed
5.
Zurück zum Zitat Dassopoulos T, Cohen RD, Scherl EJ, Schwartz RM, Kosinski L, Regueiro MD. Ulcerative colitis care pathway. Gastroenterology. 2015;149(1):238–45.CrossRefPubMed Dassopoulos T, Cohen RD, Scherl EJ, Schwartz RM, Kosinski L, Regueiro MD. Ulcerative colitis care pathway. Gastroenterology. 2015;149(1):238–45.CrossRefPubMed
6.
Zurück zum Zitat Dias CC, Rodrigues PP, Costa-Pereira A, Magro F. Clinical predictors of colectomy in patients with ulcerative colitis: systematic review and meta-analysis of cohort studies. J Crohns Colitis. 2015;9(2):156–63.CrossRefPubMed Dias CC, Rodrigues PP, Costa-Pereira A, Magro F. Clinical predictors of colectomy in patients with ulcerative colitis: systematic review and meta-analysis of cohort studies. J Crohns Colitis. 2015;9(2):156–63.CrossRefPubMed
7.
Zurück zum Zitat Solberg IC, Høivik ML, Cvancarova M, Moum B, IBSEN Study Group. Risk matrix model for prediction of colectomy in a population-based study of ulcerative colitis patients (the IBSEN study). Scand J Gastroenterol. 2015;50(12):1456–62.CrossRefPubMed Solberg IC, Høivik ML, Cvancarova M, Moum B, IBSEN Study Group. Risk matrix model for prediction of colectomy in a population-based study of ulcerative colitis patients (the IBSEN study). Scand J Gastroenterol. 2015;50(12):1456–62.CrossRefPubMed
8.
Zurück zum Zitat Carbonnel F, et al. Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther. 2000;14(3):273–9.CrossRefPubMed Carbonnel F, et al. Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther. 2000;14(3):273–9.CrossRefPubMed
9.
Zurück zum Zitat Issa M, Vijayapal A, Graham MB, Beaulieu DB, Otterson MF, Lundeen S, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5(3):345–51.CrossRefPubMed Issa M, Vijayapal A, Graham MB, Beaulieu DB, Otterson MF, Lundeen S, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5(3):345–51.CrossRefPubMed
10.
Zurück zum Zitat Jones A, McCurdy JD, Loftus EV Jr, Bruining DH, Enders FT, Killian JM, et al. Effects of antiviral therapy for patients with inflammatory bowel disease and a positive intestinal biopsy for cytomegalovirus. Clin Gastroenterol Hepatol. 2015;13(5):949–55.CrossRefPubMed Jones A, McCurdy JD, Loftus EV Jr, Bruining DH, Enders FT, Killian JM, et al. Effects of antiviral therapy for patients with inflammatory bowel disease and a positive intestinal biopsy for cytomegalovirus. Clin Gastroenterol Hepatol. 2015;13(5):949–55.CrossRefPubMed
13.
Zurück zum Zitat Pola S, Patel D, Ramamoorthy S, McLemore E, Fahmy M, Rivera–Nieves J, et al. Strategies for the care of adults hospitalized for active ulcerative colitis. Clin Gastroenterol Hepatol. 2012;10(12):1315–1325.e4.CrossRefPubMedPubMedCentral Pola S, Patel D, Ramamoorthy S, McLemore E, Fahmy M, Rivera–Nieves J, et al. Strategies for the care of adults hospitalized for active ulcerative colitis. Clin Gastroenterol Hepatol. 2012;10(12):1315–1325.e4.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Gordon GL, Zakko S, Murthy U, Sedghi S, Pruitt R, Barrett AC, et al. Once-daily mesalamine formulation for maintenance of remission in ulcerative colitis: a randomized, placebo-controlled clinical trial. J Clin Gastroenterol. 2016;50(4):318–25.PubMed Gordon GL, Zakko S, Murthy U, Sedghi S, Pruitt R, Barrett AC, et al. Once-daily mesalamine formulation for maintenance of remission in ulcerative colitis: a randomized, placebo-controlled clinical trial. J Clin Gastroenterol. 2016;50(4):318–25.PubMed
15.
Zurück zum Zitat Wang Y, et al. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016;4:Cd000543.PubMed Wang Y, et al. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016;4:Cd000543.PubMed
16.
Zurück zum Zitat Wang Y, Parker CE, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016;9(5):CD000544. Wang Y, Parker CE, Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016;9(5):CD000544.
17.
Zurück zum Zitat Yamamoto T, Shimoyama T, Matsumoto K. Consecutive monitoring of faecal calprotectin during mesalazine suppository therapy for active rectal inflammation in ulcerative colitis. Aliment Pharmacol Ther. 2015;42(5):549–58.CrossRefPubMed Yamamoto T, Shimoyama T, Matsumoto K. Consecutive monitoring of faecal calprotectin during mesalazine suppository therapy for active rectal inflammation in ulcerative colitis. Aliment Pharmacol Ther. 2015;42(5):549–58.CrossRefPubMed
18.
Zurück zum Zitat Osterman MT, Aberra FN, Cross R, Liakos S, McCabe R, Shafran I, et al. Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol. 2014;12(11):1887–93.e3.CrossRefPubMedPubMedCentral Osterman MT, Aberra FN, Cross R, Liakos S, McCabe R, Shafran I, et al. Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol. 2014;12(11):1887–93.e3.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Boyle M, Ting A, Cury DB, Nanda K, Cheifetz AS, Moss A. Adherence to rectal mesalamine in patients with ulcerative colitis. Inflamm Bowel Dis. 2015;21(12):2873–8.CrossRefPubMed Boyle M, Ting A, Cury DB, Nanda K, Cheifetz AS, Moss A. Adherence to rectal mesalamine in patients with ulcerative colitis. Inflamm Bowel Dis. 2015;21(12):2873–8.CrossRefPubMed
20.
Zurück zum Zitat Sherlock ME, MacDonald JK, Griffiths AM, Steinhart AH, Seow CH. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2015;26(10):CD007698. Sherlock ME, MacDonald JK, Griffiths AM, Steinhart AH, Seow CH. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2015;26(10):CD007698.
21.
Zurück zum Zitat Cohen RD, Dalal SR. Systematic review: rectal therapies for the treatment of distal forms of ulcerative colitis. Inflamm Bowel Dis. 2015;21(7):1719–36.CrossRefPubMed Cohen RD, Dalal SR. Systematic review: rectal therapies for the treatment of distal forms of ulcerative colitis. Inflamm Bowel Dis. 2015;21(7):1719–36.CrossRefPubMed
22.
Zurück zum Zitat Carbonnel F, Colombel JF, Filippi J, Katsanos KH, Peyrin-Biroulet L, Allez M, et al. Methotrexate is not superior to placebo for inducing steroid-free remission, but induces steroid-free clinical remission in a larger proportion of patients with ulcerative colitis. Gastroenterology. 2016;150(2):380–8.e4.CrossRefPubMed Carbonnel F, Colombel JF, Filippi J, Katsanos KH, Peyrin-Biroulet L, Allez M, et al. Methotrexate is not superior to placebo for inducing steroid-free remission, but induces steroid-free clinical remission in a larger proportion of patients with ulcerative colitis. Gastroenterology. 2016;150(2):380–8.e4.CrossRefPubMed
23.
Zurück zum Zitat Macaluso FS, Renna S, Cottone M, Orlando A. The METEOR trial: the burial of methotrexate in ulcerative colitis? Gastroenterology. 2016;151(1):211–2.CrossRefPubMed Macaluso FS, Renna S, Cottone M, Orlando A. The METEOR trial: the burial of methotrexate in ulcerative colitis? Gastroenterology. 2016;151(1):211–2.CrossRefPubMed
24.
Zurück zum Zitat • Panaccione R, Ghosh S, Middleton S, Márquez JR, Scott BB, Flint L, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146(2):392–400.e3. Demonstrates the importance of combination therapy with infliximab and azathioprine over either agent along in UC; ultimately changing treatment paradigms. CrossRefPubMed • Panaccione R, Ghosh S, Middleton S, Márquez JR, Scott BB, Flint L, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146(2):392–400.e3. Demonstrates the importance of combination therapy with infliximab and azathioprine over either agent along in UC; ultimately changing treatment paradigms. CrossRefPubMed
25.
Zurück zum Zitat Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710.CrossRefPubMed Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710.CrossRefPubMed
26.
Zurück zum Zitat Afif W, Loftus EV, Faubion WA, Kane SV, Bruining DH, Hanson KA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105(5):1133–9.CrossRefPubMed Afif W, Loftus EV, Faubion WA, Kane SV, Bruining DH, Hanson KA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105(5):1133–9.CrossRefPubMed
27.
Zurück zum Zitat Imaeda H, Bamba S, Takahashi K, Fujimoto T, Ban H, Tsujikawa T, et al. Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn’s disease under scheduled maintenance treatment. J Gastroenterol. 2014;49(4):674–82.CrossRefPubMed Imaeda H, Bamba S, Takahashi K, Fujimoto T, Ban H, Tsujikawa T, et al. Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn’s disease under scheduled maintenance treatment. J Gastroenterol. 2014;49(4):674–82.CrossRefPubMed
28.
Zurück zum Zitat Marini JC, Sendecki J, Cornillie F, Popp JW, Black S, Blank M, et al. Comparisons of serum infliximab and antibodies-to-infliximab tests used in inflammatory bowel disease clinical trials of Remicade®. AAPS J. 2017;19(1):161–71.CrossRefPubMed Marini JC, Sendecki J, Cornillie F, Popp JW, Black S, Blank M, et al. Comparisons of serum infliximab and antibodies-to-infliximab tests used in inflammatory bowel disease clinical trials of Remicade®. AAPS J. 2017;19(1):161–71.CrossRefPubMed
29.
Zurück zum Zitat Roblin X, Marotte H, Rinaudo M, del Tedesco E, Moreau A, Phelip JM, et al. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014;12(1):80–84.e2.CrossRefPubMed Roblin X, Marotte H, Rinaudo M, del Tedesco E, Moreau A, Phelip JM, et al. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014;12(1):80–84.e2.CrossRefPubMed
30.
Zurück zum Zitat Paul S, del Tedesco E, Marotte H, Rinaudo-Gaujous M, Moreau A, Phelip JM, et al. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2013;19(12):2568–76.CrossRefPubMed Paul S, del Tedesco E, Marotte H, Rinaudo-Gaujous M, Moreau A, Phelip JM, et al. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2013;19(12):2568–76.CrossRefPubMed
31.
Zurück zum Zitat Yanai H, Lichtenstein L, Assa A, Mazor Y, Weiss B, Levine A, et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol. 2015;13(3):522–30.CrossRefPubMed Yanai H, Lichtenstein L, Assa A, Mazor Y, Weiss B, Levine A, et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol. 2015;13(3):522–30.CrossRefPubMed
32.
Zurück zum Zitat •• Vande Casteele N, Ferrante M, van Assche G, Ballet V, Compernolle G, van Steen K, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148(7):1320–9.e3. A randomized controlled trial of prospective therapeutic drug monitoring of infliximab showed no benefit at 1 year of concentration-based dosing as compared to clinically based dosing CrossRefPubMed •• Vande Casteele N, Ferrante M, van Assche G, Ballet V, Compernolle G, van Steen K, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148(7):1320–9.e3. A randomized controlled trial of prospective therapeutic drug monitoring of infliximab showed no benefit at 1 year of concentration-based dosing as compared to clinically based dosing CrossRefPubMed
33.
Zurück zum Zitat Papamichael K, Chachu KA, Vajravelu RK, Vaughn BP, Ni J, Osterman MT, et al. Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared with reactive monitoring of serum concentrations of infliximab. Clin Gastroenterol Hepatol. 2017;15(10):1580–1588.e3.CrossRefPubMed Papamichael K, Chachu KA, Vajravelu RK, Vaughn BP, Ni J, Osterman MT, et al. Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared with reactive monitoring of serum concentrations of infliximab. Clin Gastroenterol Hepatol. 2017;15(10):1580–1588.e3.CrossRefPubMed
34.
Zurück zum Zitat Vaughn BP, Martinez-Vazquez M, Patwardhan VR, Moss AC, Sandborn WJ, Cheifetz AS. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. Inflamm Bowel Dis. 2014;20(11):1996–2003.CrossRefPubMedPubMedCentral Vaughn BP, Martinez-Vazquez M, Patwardhan VR, Moss AC, Sandborn WJ, Cheifetz AS. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. Inflamm Bowel Dis. 2014;20(11):1996–2003.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Vande Casteele N, Herfarth H, Katz J, Falck-Ytter Y, Singh S. American Gastroenterological Association Institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases. Gastroenterology. 2017;153(3):835–857.e6.CrossRefPubMed Vande Casteele N, Herfarth H, Katz J, Falck-Ytter Y, Singh S. American Gastroenterological Association Institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases. Gastroenterology. 2017;153(3):835–857.e6.CrossRefPubMed
36.
Zurück zum Zitat Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S, Gerson L, et al. American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology. 2017;153(3):827–34.CrossRefPubMed Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S, Gerson L, et al. American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology. 2017;153(3):827–34.CrossRefPubMed
37.
Zurück zum Zitat Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet. 2012;380(9857):1909–15.CrossRefPubMed Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet. 2012;380(9857):1909–15.CrossRefPubMed
38.
Zurück zum Zitat Duijvis NW, ten Hove AS, Ponsioen CIJ, van den Brink GR, Buskens CJ, Bemelman WA, et al. Similar short- and long-term colectomy rates with ciclosporin and infliximab treatment in hospitalised ulcerative colitis patients. J Crohns Colitis. 2016;10(7):821–7.CrossRefPubMed Duijvis NW, ten Hove AS, Ponsioen CIJ, van den Brink GR, Buskens CJ, Bemelman WA, et al. Similar short- and long-term colectomy rates with ciclosporin and infliximab treatment in hospitalised ulcerative colitis patients. J Crohns Colitis. 2016;10(7):821–7.CrossRefPubMed
39.
Zurück zum Zitat Gibson DJ, Heetun ZS, Redmond CE, Nanda KS, Keegan D, Byrne K, et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13(2):330–5.CrossRefPubMed Gibson DJ, Heetun ZS, Redmond CE, Nanda KS, Keegan D, Byrne K, et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13(2):330–5.CrossRefPubMed
40.
Zurück zum Zitat Brandse JF, van den Brink GR, Wildenberg ME, van der Kleij D, Rispens T, Jansen JM, et al. Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology. 2015;149(2):350–5.e2.CrossRefPubMed Brandse JF, van den Brink GR, Wildenberg ME, van der Kleij D, Rispens T, Jansen JM, et al. Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology. 2015;149(2):350–5.e2.CrossRefPubMed
41.
Zurück zum Zitat Herfarth HH, Rogler G, Higgins PD. Pushing the pedal to the metal: should we accelerate infliximab therapy for patients with severe ulcerative colitis? Clin Gastroenterol Hepatol. 2015;13(2):336–8.CrossRefPubMed Herfarth HH, Rogler G, Higgins PD. Pushing the pedal to the metal: should we accelerate infliximab therapy for patients with severe ulcerative colitis? Clin Gastroenterol Hepatol. 2015;13(2):336–8.CrossRefPubMed
42.
Zurück zum Zitat Vermeire S, O'Byrne S, Keir M, Williams M, Lu TT, Mansfield JC, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet. 2014;384(9940):309–18.CrossRefPubMed Vermeire S, O'Byrne S, Keir M, Williams M, Lu TT, Mansfield JC, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet. 2014;384(9940):309–18.CrossRefPubMed
43.
Zurück zum Zitat Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367(7):616–24.CrossRefPubMed Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367(7):616–24.CrossRefPubMed
44.
Zurück zum Zitat •• Sandborn WJ, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723–36. A first in class oral small molecule agent for induction and maintenance of UC will provide a needed new class of therapy once approved in 2018 CrossRefPubMed •• Sandborn WJ, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723–36. A first in class oral small molecule agent for induction and maintenance of UC will provide a needed new class of therapy once approved in 2018 CrossRefPubMed
45.
Zurück zum Zitat Langhorst J, Anthonisen IB, Steder-Neukamm U, Lüdtke R, Spahn G, Michalsen A, et al. Amount of systemic steroid medication is a strong predictor for the use of complementary and alternative medicine in patients with inflammatory bowel disease: results from a German national survey. Inflamm Bowel Dis. 2005;11(3):287–95.CrossRefPubMed Langhorst J, Anthonisen IB, Steder-Neukamm U, Lüdtke R, Spahn G, Michalsen A, et al. Amount of systemic steroid medication is a strong predictor for the use of complementary and alternative medicine in patients with inflammatory bowel disease: results from a German national survey. Inflamm Bowel Dis. 2005;11(3):287–95.CrossRefPubMed
46.
Zurück zum Zitat Lang A, Salomon N, Wu JCY, Kopylov U, Lahat A, Har-Noy O, et al. Curcumin in combination with mesalamine induces remission in patients with mild-to-moderate ulcerative colitis in a randomized controlled trial. Clin Gastroenterol Hepatol. 2015;13(8):1444–9.e1.CrossRefPubMed Lang A, Salomon N, Wu JCY, Kopylov U, Lahat A, Har-Noy O, et al. Curcumin in combination with mesalamine induces remission in patients with mild-to-moderate ulcerative colitis in a randomized controlled trial. Clin Gastroenterol Hepatol. 2015;13(8):1444–9.e1.CrossRefPubMed
47.
Zurück zum Zitat Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006;4(12):1502–6.CrossRefPubMed Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006;4(12):1502–6.CrossRefPubMed
48.
Zurück zum Zitat Frolkis AD, Dykeman J, Negrón ME, deBruyn J, Jette N, Fiest KM, et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology. 2013;145(5):996–1006.CrossRefPubMed Frolkis AD, Dykeman J, Negrón ME, deBruyn J, Jette N, Fiest KM, et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology. 2013;145(5):996–1006.CrossRefPubMed
49.
Zurück zum Zitat Reich KM, Chang HJ, Rezaie A, Wang H, Goodman KJ, Kaplan GG, et al. The incidence rate of colectomy for medically refractory ulcerative colitis has declined in parallel with increasing anti-TNF use: a time-trend study. Aliment Pharmacol Ther. 2014;40(6):629–38.CrossRefPubMed Reich KM, Chang HJ, Rezaie A, Wang H, Goodman KJ, Kaplan GG, et al. The incidence rate of colectomy for medically refractory ulcerative colitis has declined in parallel with increasing anti-TNF use: a time-trend study. Aliment Pharmacol Ther. 2014;40(6):629–38.CrossRefPubMed
50.
Zurück zum Zitat Peyrin-Biroulet L, Germain A, Patel AS, Lindsay JO. Systematic review: outcomes and post-operative complications following colectomy for ulcerative colitis. Aliment Pharmacol Ther. 2016;44(8):807–16.CrossRefPubMed Peyrin-Biroulet L, Germain A, Patel AS, Lindsay JO. Systematic review: outcomes and post-operative complications following colectomy for ulcerative colitis. Aliment Pharmacol Ther. 2016;44(8):807–16.CrossRefPubMed
51.
Zurück zum Zitat Pabby V, Oza SS, Dodge LE, Hacker MR, Moragianni VA, Correia K, et al. In vitro fertilization is successful in women with ulcerative colitis and Ileal pouch anal anastomosis. Am J Gastroenterol. 2015;110(6):792–7.CrossRefPubMed Pabby V, Oza SS, Dodge LE, Hacker MR, Moragianni VA, Correia K, et al. In vitro fertilization is successful in women with ulcerative colitis and Ileal pouch anal anastomosis. Am J Gastroenterol. 2015;110(6):792–7.CrossRefPubMed
52.
Zurück zum Zitat Beyer-Berjot L, Maggiori L, Birnbaum D, Lefevre JH, Berdah S, Panis Y. A total laparoscopic approach reduces the infertility rate after ileal pouch-anal anastomosis: a 2-center study. Ann Surg. 2013;258(2):275–82.CrossRefPubMed Beyer-Berjot L, Maggiori L, Birnbaum D, Lefevre JH, Berdah S, Panis Y. A total laparoscopic approach reduces the infertility rate after ileal pouch-anal anastomosis: a 2-center study. Ann Surg. 2013;258(2):275–82.CrossRefPubMed
53.
Zurück zum Zitat Bartels SA, et al. Significantly increased pregnancy rates after laparoscopic restorative proctocolectomy: a cross-sectional study. Ann Surg. 2012;256(6):1045–8.CrossRefPubMed Bartels SA, et al. Significantly increased pregnancy rates after laparoscopic restorative proctocolectomy: a cross-sectional study. Ann Surg. 2012;256(6):1045–8.CrossRefPubMed
Metadaten
Titel
Contemporary Management of Ulcerative Colitis
verfasst von
Rohini Vanga
Millie D. Long
Publikationsdatum
01.03.2018
Verlag
Springer US
Erschienen in
Current Gastroenterology Reports / Ausgabe 3/2018
Print ISSN: 1522-8037
Elektronische ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-018-0622-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.